3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
3
Withdrawn
1
Unknown
1
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
217
Breast
88
Head & Neck
13
Other solid neoplasm
8
Tumor-Agnostic
5
Other neoplasm
2
NET
2
Lymphoid
2
Endocrine
2
Thoracic
1
Sarcoma
1
Gynecologic
1
Dermatologic
1
CNS
1
Conditions
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Sarcoma
1
Pancreatic Neoplasms
1
Lymphoma, T-Cell, Cutaneous
1
Lymphoma
1
Colonic Neoplasms
1
Carcinoma, Basal Cell
1
Breast Neoplasms
1
Interventions
Doxorubicin
25
Radiotherapy
16
apatinib
15
Cyclophosphamide
15
Ifosfamide
13
anlotinib
12
camrelizumab
10
Temozolomide
9
Imatinib Mesylate
9
Vincristine
8
Surgical Procedures, Operative
7
Neoadjuvant Therapy
7
Methotrexate
7
Drug Therapy
7
Dactinomycin
5
Blood Specimen Collection
5
fludarabine phosphate
4
Paclitaxel
4
Immune Checkpoint Inhibitors
4
Etoposide
4
Docetaxel
4
Carboplatin
4
toripalimab
3
pembrolizumab
3
Trabectedin
3
Topotecan
3
Surveys and Questionnaires
3
Radiation Dose Hypofractionation
3
Nivolumab
3
Melphalan
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Unknown
×
Capecitabine
×
Sarcoma
×
Clear all
NCT03775525
2022-12-23
GEN602
Genzada Pharmaceuticals USA, Inc.
Phase 1
Unknown
127 enrolled